Generic SORBITOL INN entry, pharmaceutical patent expiration information and freedom to operate

Sponsor	Phase
Applied Therapeutics, Inc.	PHASE3
Sunnybrook Health Sciences Centre	PHASE3
Empros Pharma AB	PHASE2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	SORBITOL 3% IN PLASTIC CONTAINER	sorbitol	SOLUTION;IRRIGATION	018512-001	May 27, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
B Braun	SORBITOL 3.3% IN PLASTIC CONTAINER	sorbitol	SOLUTION;IRRIGATION	016741-001	Approved Prior to Jan 1, 1982		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Baxter Hlthcare	SORBITOL 3% IN PLASTIC CONTAINER	sorbitol	SOLUTION;IRRIGATION	017863-001	Approved Prior to Jan 1, 1982		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 5, 2026

Sorbitol is a mature, low-cost polyol used in pharmaceuticals as an excipient, osmotic laxative, humectant, sweetener, and vehicle. It is not a single branded pharmaceutical product with a discrete patent cliff. The commercial market is driven by bulk ingredient supply, pharmaceutical-grade quality, formulation demand, and manufacturing economics rather than exclusivity.

The market has low patent protection, multiple global suppliers, limited regulatory barriers for conventional formulations, and strong substitution risk from mannitol, xylitol, glycerin, polyethylene glycol, and other excipients. Public companies generally do not report sorbitol revenue separately, preventing a reliable standalone revenue forecast.

What is sorbitol used for in pharmaceutical products?

Sorbitol is a six-carbon sugar alcohol derived primarily from glucose. Pharmaceutical applications include:

Application	Function	Commercial relevance
Oral liquids	Sweetener, humectant, viscosity modifier, vehicle	High-volume use in syrups, solutions, and suspensions
Chewable tablets	Bulking agent and taste-masking excipient	Used where sugar-free formulations are required
Osmotic laxatives	Active ingredient or supporting excipient	Sold in oral and rectal products, depending on formulation
Capsules and solid doses	Filler and stabilizer	Lower-value use than liquid formulations
Dental and throat products	Non-cariogenic sweetener and moisture-retention agent	Used in oral-care and lozenge products
Biologic and injectable formulations	Stabilizer or tonicity modifier in selected products	Smaller volume but higher quality requirements
Topical products	Humectant and texture modifier	Used in creams, gels, and liquid preparations

Pharmaceutical-grade sorbitol is commonly supplied as crystalline powder, granular material, or aqueous solution, including approximately 70% sorbitol solutions. The required specification depends on the route of administration and dosage form.

How large is the pharmaceutical sorbitol market?

The pharmaceutical segment is part of a broader sorbitol market that includes food, oral care, cosmetics, industrial chemicals, and vitamin products. Public market studies estimate the overall sorbitol market in the billions of dollars, but reported figures differ because analysts apply different definitions, geographies, and inclusion rules.

No major public supplier discloses a separately audited pharmaceutical-sorbitol revenue line. Roquette, Ingredion, ADM, Cargill, Gulshan Polyols, and Asian producers report broader sweetener, polyol, starch, or specialty-ingredient categories rather than sorbitol alone.[1][2]

The commercial market can be divided into three tiers:

Bulk commodity sorbitol: Primarily used in food, toothpaste, and industrial applications. Price and capacity determine competitiveness.
Pharmaceutical-grade sorbitol: Requires compliance with pharmacopeial specifications, validated production, controlled impurities, and supply documentation.
Specialty grades and solutions: Include low-endotoxin, injectable-compatible, customized concentration, and application-specific products.

Pharmaceutical-grade material has higher qualification barriers than food-grade sorbitol, but the underlying molecule remains commoditized. Margin expansion depends on quality systems, reliable supply, regulatory support, and customer switching costs.

What is the financial trajectory for sorbitol suppliers?

The likely financial trajectory is stable volume growth with limited structural pricing power. Sorbitol demand benefits from:

Growth in generic oral liquids and pediatric medicines.
Expansion of sugar-free formulations.
Increased use of excipients in emerging pharmaceutical markets.
Demand for oral-care products and pharmaceutical syrups.
Broader use of plant-derived and fermentation-based ingredients.

Profitability is constrained by:

Glucose or starch feedstock prices.
Hydrogenation energy costs.
Freight and packaging expenses.
Competition from Chinese, Indian, Indonesian, and European producers.
Substitution by mannitol, glycerin, polyethylene glycol, and other excipients.
Customer pressure to dual-source and reduce ingredient costs.

Sorbitol producers with integrated glucose, starch, or corn-processing operations have an advantage because feedstock conversion and logistics represent a significant portion of total cost. Producers that purchase feedstock externally face greater exposure to agricultural prices.

Revenue exposure of major suppliers

Supplier	Public sorbitol disclosure	Strategic position
Roquette	Not separately disclosed in public reporting	Major global polyol and pharmaceutical excipient supplier
Ingredion	Not separately disclosed	Integrated starch and sweetener producer with pharmaceutical capabilities
ADM	Not separately disclosed	Large agricultural processor with relevant carbohydrate feedstocks
Cargill	Private; sorbitol revenue not separately disclosed	Global food and specialty-ingredient supplier
Gulshan Polyols	Product-level visibility is limited	Indian producer with polyol and sweetener exposure
Ecogreen Oleochemicals	Private-company disclosure is limited	Large Asian polyol supplier
PT Sorini Agro Asia Corporindo	Limited public standalone disclosure	Indonesian sorbitol and polyol producer

A supplier’s sorbitol earnings are usually more sensitive to utilization rates and feedstock spreads than to pharmaceutical patent events. The most likely financial outcome is modest market expansion, stable competition, and periodic margin volatility.

What regulatory status does sorbitol have with the FDA?

Sorbitol is recognized in the United States as an established excipient and food ingredient. FDA’s Inactive Ingredient Database lists sorbitol across multiple dosage forms and routes, subject to concentration and product-specific conditions.[3]

Its regulatory position includes:

Use as an inactive ingredient in approved drug products.
Use in over-the-counter and prescription oral formulations.
Use as a sweetener, humectant, bulking agent, and vehicle.
Use in selected products as an osmotic laxative.
Food and pharmaceutical applications governed by separate regulatory frameworks.

Sorbitol is also covered by pharmacopeial standards, including United States Pharmacopeia-National Formulary specifications. Pharmaceutical manufacturers typically qualify the supplier, grade, concentration, impurity profile, microbial quality, and documentation package before use.[4]

The FDA’s inactive-ingredient listing does not constitute approval of every concentration, route, or formulation. A manufacturer must still demonstrate that the finished product is safe, effective, and compliant with applicable quality requirements.

What is the Orange Book status of sorbitol?

Sorbitol itself does not have a meaningful standalone Orange Book patent estate. The FDA Orange Book lists approved drug products and certain patents or exclusivity information associated with those products, not every excipient sold into the pharmaceutical supply chain.[5]

The practical consequences are:

No molecule-level Orange Book exclusivity for sorbitol.
No branded sorbitol innovator product comparable to a new chemical entity.
No general sorbitol patent cliff.
Orange Book risk must be assessed product by product.
Patents may cover a finished formulation, dosing regimen, delivery device, or combination rather than sorbitol itself.

A generic applicant using sorbitol in a formulation may face patents covering the finished product, but those patents do not create broad exclusivity over sorbitol supply.

What patents protect pharmaceutical sorbitol products?

Most broad composition-of-matter protection for sorbitol is unavailable because the compound has been known and commercially used for decades. Patent activity is more likely to concern:

Specific liquid formulations.
Stabilized oral solutions.
Low-calorie or sugar-free dosage forms.
Controlled-release preparations.
Combination laxative products.
Taste-masking systems.
Sorbitol-containing ophthalmic or topical formulations.
Manufacturing methods that improve purity, crystallinity, or particle size.
Packaging systems that limit degradation or microbial growth.

A formulation patent must satisfy novelty, non-obviousness, enablement, and written-description requirements. The presence of sorbitol in a claim does not automatically create a commercially meaningful barrier if alternative excipients can produce the same result.

Patent strength by claim category

Claim category	Typical strength	Generic or competitor risk
Sorbitol molecule	Very low	Very high
Pharmaceutical-grade purity specification	Low to moderate	High if specifications are routine
Broad oral syrup containing sorbitol	Low	High
Narrow concentration and stabilizer combination	Moderate	Moderate
Controlled-release sorbitol formulation	Moderate to high if technically supported	Depends on design-around options
Manufacturing process	Moderate	Competitors may use different processes
Device or packaging claim	Moderate	Depends on product architecture
Method-of-use claim	Variable	Depends on indication and claim scope

Patent expiration dates cannot be assigned to “pharmaceutical sorbitol” as a category. They must be linked to a specific patent family and product. Many historical patents covering conventional sorbitol formulations are likely expired or near the end of their terms, while newer formulation patents may remain in force.

Are there Paragraph IV challenges involving sorbitol?

There is no broad Paragraph IV campaign directed at sorbitol as an active ingredient. Paragraph IV litigation would arise only where an abbreviated new drug application challenges an Orange Book-listed patent for a specific sorbitol-containing drug product.

The risk profile is therefore product-specific:

Standard sorbitol oral solutions generally have low patent exposure.
Branded combination laxatives may carry formulation or method-of-use patents.
Complex dosage forms can create greater certification and litigation risk.
A generic applicant may use a Paragraph IV certification, a Section VIII statement, or a non-infringing formulation depending on the listed claims.

The absence of a molecule-level patent does not eliminate litigation involving a particular finished product.

When does sorbitol lose exclusivity?

Sorbitol has no single exclusivity-loss date. Its core chemical and excipient use is already off-patent and open to competition.

For a particular sorbitol-containing drug, relevant dates may include:

New chemical entity exclusivity, if the product contains a different active ingredient.
Pediatric exclusivity.
Orphan-drug exclusivity.
New formulation or new indication exclusivity.
Orange Book patent expiration.
Regulatory exclusivity tied to the finished product.

In most conventional sorbitol products, market entry is controlled by formulation development, abbreviated approval requirements, manufacturing qualification, and commercial distribution rather than active-ingredient exclusivity.

What generic entry risks exist for sorbitol products?

Generic entry risk is high for simple oral solutions, syrups, and conventional laxatives. Development costs are comparatively low, and the active ingredient is widely available from qualified suppliers.

Risk rises when the product has:

A proprietary delivery device.
A complex suspension or emulsion.
Controlled release.
Narrow impurity limits.
Sterile manufacturing requirements.
A difficult taste or stability profile.
A combination of active ingredients.
A narrow method-of-use claim.
A supplier-specific grade that is difficult to replace.

Generic competitors may also avoid a patent by replacing sorbitol with mannitol, glycerin, maltitol, polyethylene glycol, or another functionally equivalent excipient, provided the finished product meets regulatory requirements.

How does sorbitol compare with competing excipients?

Excipient	Main advantages	Main disadvantages	Competitive effect
Sorbitol	Sweet, water-soluble, low cost, useful in liquids	Gastrointestinal tolerance limits at high doses	Strong in oral liquids and sugar-free products
Mannitol	Low hygroscopicity, useful in tablets and lyophilized products	Less sweet, higher cost in some grades	Strong substitute in solid and injectable applications
Glycerin	Effective humectant and solvent	Taste, viscosity, and handling limitations	Competes in liquids and topical products
Polyethylene glycol	Strong osmotic and solubilizing properties	Different sensory and formulation profile	Competes in laxatives and liquid formulations
Xylitol	Sweet, cooling sensation, dental benefits	Cost and gastrointestinal tolerance	Competes in oral care and sugar-free products
Sucrose	Strong taste profile and low cost	Caloric, cariogenic, unsuitable for some patients	Remains a benchmark in oral syrups

Sorbitol’s competitive position is strongest where sweetness, water solubility, moisture retention, and cost must be combined. It is weaker where low hygroscopicity, high chemical stability, or specialized parenteral performance is required.

What manufacturing and intellectual-property barriers affect sorbitol?

Sorbitol is manufactured mainly by catalytic hydrogenation of glucose or glucose-containing intermediates. Key manufacturing requirements include:

Consistent feedstock quality.
Hydrogenation catalyst control.
Removal of residual impurities.
Control of mannitol and other polyol byproducts.
Crystallization or solution-concentration control.
Microbial and endotoxin management where required.
Compliance with GMP and pharmacopeial standards.
Batch traceability and change-control systems.

The main barriers are operational rather than patent-based. A new supplier may produce chemically acceptable sorbitol but still fail pharmaceutical qualification because of inconsistent impurities, documentation gaps, manufacturing changes, or inadequate regulatory support.

Customers often qualify more than one supplier, but switching can require stability work, regulatory filings, validation, and quality audits. That creates a moderate commercial barrier even when legal exclusivity is absent.

What licensing deals and litigation affect sorbitol?

Sorbitol is generally sold through supply agreements, quality agreements, and distribution arrangements rather than high-value pharmaceutical licensing deals. Publicly disclosed milestone-based licensing transactions centered specifically on sorbitol are uncommon.

Commercial agreements typically address:

Minimum purchase volumes.
Price adjustment formulas.
Feedstock or energy pass-through mechanisms.
Geographic supply rights.
Pharmaceutical-grade change control.
Audit rights.
Regulatory documentation.
Continuity-of-supply obligations.

Litigation risk is more likely to involve product liability, supply interruption, specification disputes, or finished-drug formulation patents than ownership of the sorbitol molecule.

Is there biosimilar risk for sorbitol?

No. Sorbitol is a small-molecule chemical and excipient, not a biologic. Biosimilar pathways do not apply.

The relevant competitive threats are:

Generic finished drugs.
Alternative excipients.
Private-label laxative products.
Contract manufacturers.
Regional pharmaceutical suppliers.
Food-grade material entering lower-risk applications.
Vertical integration by large carbohydrate processors.

What generic launch scenarios are most likely?

Scenario 1: Conventional oral solution

This is the highest-risk segment for incumbent branded products. A competitor can source sorbitol from multiple suppliers and develop a relatively simple aqueous formulation.

Scenario 2: Branded combination laxative

Entry depends on the combination, labeling, Orange Book patents, and whether the generic can match the reference product’s formulation and dosing instructions.

Scenario 3: Sterile or specialty formulation

Entry is slower because of facility requirements, microbial controls, stability testing, and more demanding regulatory documentation.

Scenario 4: Pharmaceutical-grade ingredient supply

Competition is continuous rather than cliff-based. Customers may dual-source, but qualified suppliers retain value through consistency, regulatory support, and supply reliability.

How strong is the overall sorbitol patent estate?

The estate is weak at the molecule level and moderate only in narrow formulation, manufacturing, or delivery applications. No single patent family is likely to control the global pharmaceutical sorbitol market.

Factor	Assessment
Composition-of-matter protection	Weak or unavailable
Broad excipient claims	Weak
Narrow formulation claims	Variable
Manufacturing-process claims	Moderate in limited cases
Regulatory barriers	Moderate for pharmaceutical grade
Supplier concentration	Meaningful but regionally variable
Generic substitution risk	High
Biosimilar risk	Not applicable
Pricing power	Limited
Long-term demand	Stable to moderately growing

Key Takeaways

Sorbitol is a mature pharmaceutical excipient and laxative ingredient, not a single protected drug franchise.
No standalone Orange Book exclusivity or molecule-level patent cliff controls the market.
Pharmaceutical-grade supply has higher qualification barriers than food-grade supply, but the molecule is widely available.
Simple oral liquids and conventional laxatives face high generic and substitution risk.
Supplier economics depend on glucose feedstock, manufacturing utilization, energy, logistics, and quality systems.
Public companies do not generally report sorbitol revenue separately, so standalone financial forecasts are not verifiable from public filings.
Formulation, manufacturing, packaging, and method-of-use patents may affect individual products but do not broadly protect sorbitol.
No biosimilar pathway applies because sorbitol is a small-molecule chemical.
The most defensible commercial assets are reliable pharmaceutical-grade production, regulatory documentation, dual-site capacity, and customer qualification status.

FAQs

Is sorbitol an active pharmaceutical ingredient or an excipient?

It can be either. In many products it is an inactive excipient used for sweetness, viscosity, moisture retention, or formulation stability. In selected laxative products, it can function as the active osmotic ingredient.

Can a company patent sorbitol for pharmaceutical use?

A company generally cannot obtain broad new patent protection over the known sorbitol molecule. It may obtain narrower patents covering a specific formulation, manufacturing process, delivery system, concentration, or therapeutic use if the claims meet patentability standards.

Which companies are major pharmaceutical-grade sorbitol suppliers?

Major global and regional suppliers include Roquette, Ingredion, Cargill, ADM, Gulshan Polyols, Ecogreen Oleochemicals, and PT Sorini, although product-level market shares and pharmaceutical revenue are not generally disclosed.

Is pharmaceutical-grade sorbitol interchangeable with food-grade sorbitol?

Not automatically. Pharmaceutical use requires appropriate specifications, GMP controls, documentation, impurity limits, and regulatory qualification. A food-grade material may not meet the requirements for a particular drug product.

What is the main investment risk in the sorbitol market?

The principal risk is commoditization. Excess capacity, low switching costs, alternative excipients, agricultural feedstock volatility, and limited patent protection can constrain margins even when demand grows.

References

Ingredion Incorporated. (2024). 2023 annual report.
Archer-Daniels-Midland Company. (2024). 2023 annual report.
U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	143
Clinical Trials:	40
What excipients (inactive ingredients) are in sorbitol?	sorbitol excipients list
DailyMed Link:	sorbitol at DailyMed

Sorbitol - Generic Drug Details

What are the generic drug sources for sorbitol and what is the scope of patent protection?

Summary for sorbitol

Recent Clinical Trials for sorbitol

Medical Subject Heading (MeSH) Categories for sorbitol

Anatomical Therapeutic Chemical (ATC) Classes for sorbitol

US Patents and Regulatory Information for sorbitol

Sorbitol Pharmaceutical Market Dynamics, Financial Trajectory, Patents, and Generic Risk